As a woman with epilepsy, who needs anticonvulsant medication to keep my seizures under reasonable control (and who is also a health professional), I contemplated pregnancy with some concern, both for my own health and that of any children I might have. I had many questions which I wanted answered. When my consultant indicated, after research of the literature and from his own experience, that some of my questions seemed to have no answer, or only a very muddled one, we set out on a joint quest to try to answer some of them better (e.g. by asking our local maternity hospital to audit the outcome of epidural anaesthesia in mothers with epilepsy undergoing this procedure).
Many uncertainties remained but we made a joint decision (as patient and doctor) to withdraw me from sodium valproate before I conceived and, later, to substitute lamotrigine. We also made a joint decision (as nurse and doctor) to try to improve our service to women with epilepsy who were seeking advice about conception and pregnancy and to try to build up our own audited experience 2 and to encourage others to do the same and to continue to monitor the literature.
Since then I have had three children (happily all healthy) and continue my interests in the management of women with epilepsy. In order to devote myself to childcare I am taking a break from nursing in an epilepsy clinic, but hope to return in a few years.
When I return can I expect to see any improvement in epilepsy service themselves, particularly in specific services for women with epilepsy? Will the Best Practice Guidelines 1 , have been implemented? Will there be published results of the various epilepsy and pregnancy registers, which have been set up? Will sufficient children have been put into these registers that we can have confidence in the results? Will further work have been done in trying to determine the causes of the foetal abnormalities that seem to occur in the children of some women with epilepsy? Will we have determined conclusively whether or not exposure to anticonvulsant drugs in the womb causes specific learning difficulty in children some years after the exposure? Will we have determined whether or not prophylactic folic acid (and if so how much) is effective in preventing foetal abnormality? Will there be enough evidence to indicate whether some of the newer antiepileptic drugs are safer in terms of foetal outcome than conventional anticonvulsants? Will doctors be taking the needs of women more seriously when they plan and discuss care of a woman's epilepsy? Will we have determined the right advice to give a woman with epilepsy who is approaching the menopause, in terms of whether she can safely take hormone replacement therapy, and, if so, what is the best therapy for her? Will we have resolved the controversy about whether the adolescent ovary is at risk from either epilepsy itself or from some of the drugs used to treat it?
When I started my own personal quest for answers, questions about pre-conception care were uppermost in my mind. I had to make a personal decision, based on what little evidence there was: my decisions were to some extent based on the 'gut feelings' of myself and my consultant. Hopefully, when I return there will be better answers to the same questions for the woman with epilepsy, derived from careful audit.
There is already a pressure group (formed of parents whose children may, or may not, have been damaged by intra uterine exposure to anticonvulsants)-The National Foetal Anticonvulsant Syndrome Association. They will no doubt become powerful advocates for research and audit. I am heartened that clinicians with an interest in this area are also beginning to discuss things together. Published in this issue of Seizure are the abstracts of a recent conference (held in Manchester) of a group of interested clinicians. It was agreed at this meeting to try to set up an association of physicians with an interest in foetal outcome in women with epilepsy, the Epilepsy in Pregnancy Group. If any reader wants to join the Group they should contact the organiser, Dr Peter Turnpenny, Clinical Genetics Services, Royal Devon & Exeter Hospital (Wonford), Exeter, EX2 5DW, UK.
The abstracts demonstrate a wide variety of approaches. Different areas have different perspectives and different agendas. What is pleasing is that there is a group of clinicians who are prepared to try to put these issues onto the research agenda.
Our own work featured in this conference and has recently been published 1 . In the discussion following the presentation of our paper most of the group felt that we were rather brave to be already removing and substituting anticonvulsants before pregnancy. Yes, I think we are, but early results have encouraged us to continue the practice (but to continue to carefully audit the results), whilst at the same time acknowledging that we have to be prepared to accept that we may be wrong. Only time will tell. The decisions that some of our patients have taken, based on what we have told them, are more informed than the decisions I had to make (with even less certainty and, less audited experience) some years ago. I had some trepidation in making these decisions but I am glad that I did and that I felt supported in this difficult decision-making and that my voice, as a patient, was listened to, acknowledged and had some influence. The other thing I hope for when I return to epilepsy in the future, is that all over the country the woman with epilepsy will have become a fully informed partner in her own health care, and that doctors have come to accept, to use my colleagues' phrase, that, in terms of their epilepsy, women are more than just a man without a penis 3 
